ATE159249T1 - 2-piperazinonverbindungen, deren herstellung und verwendung - Google Patents

2-piperazinonverbindungen, deren herstellung und verwendung

Info

Publication number
ATE159249T1
ATE159249T1 AT92307292T AT92307292T ATE159249T1 AT E159249 T1 ATE159249 T1 AT E159249T1 AT 92307292 T AT92307292 T AT 92307292T AT 92307292 T AT92307292 T AT 92307292T AT E159249 T1 ATE159249 T1 AT E159249T1
Authority
AT
Austria
Prior art keywords
group
stands
compounds
membered ring
anion
Prior art date
Application number
AT92307292T
Other languages
English (en)
Inventor
Hirosada Sugihara
Zenichi Terashita
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE159249T1 publication Critical patent/ATE159249T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92307292T 1991-08-23 1992-08-10 2-piperazinonverbindungen, deren herstellung und verwendung ATE159249T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21239791 1991-08-23
JP12314692 1992-05-15

Publications (1)

Publication Number Publication Date
ATE159249T1 true ATE159249T1 (de) 1997-11-15

Family

ID=26460144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92307292T ATE159249T1 (de) 1991-08-23 1992-08-10 2-piperazinonverbindungen, deren herstellung und verwendung

Country Status (11)

Country Link
US (1) US5294713A (de)
EP (1) EP0529858B1 (de)
KR (1) KR930004287A (de)
CN (2) CN1069730A (de)
AT (1) ATE159249T1 (de)
AU (1) AU646966B2 (de)
CA (1) CA2076619A1 (de)
DE (1) DE69222719T2 (de)
FI (1) FI923775A (de)
HU (2) HUT63154A (de)
NO (1) NO923253L (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
DE4302485A1 (de) * 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
WO1994022834A1 (en) * 1993-03-29 1994-10-13 Zeneca Limited Heterocyclic derivatives as platelet aggregation inhibitors
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
AU692439B2 (en) * 1993-03-29 1998-06-11 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
HUT70045A (en) * 1993-06-17 1995-09-28 Takeda Chemical Industries Ltd 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
CA2216162A1 (en) * 1995-04-26 1996-10-31 Takeda Chemical Industries, Ltd. Piperazinones useful as inhibitors of platelet aggregation
EP0750913A3 (de) * 1995-06-30 1997-11-05 Takeda Chemical Industries, Ltd. Disaccharide enthaltende gefriergetrocknete Zubereitung für pharmazeutische Verwendung
EP0765660A3 (de) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Mikrokapseln enthaltend 2-Piperazinon-1-essigsäure Verbindungen
AU2421797A (en) * 1996-03-15 1997-10-01 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
AU6120298A (en) 1997-03-07 1998-09-22 Takeda Chemical Industries Ltd. 2-peperazinone-1-acetic acid derivatives and their use
WO1998046628A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2002513412A (ja) * 1997-04-14 2002-05-08 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
EP0977772A1 (de) 1997-04-14 2000-02-09 Cor Therapeutics, Inc. Selektive faktor xa-inhibitoren
AU6896398A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
EP0986551B1 (de) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamidderivate, ihre herstellung und verwendung
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
US6403595B1 (en) 1998-02-05 2002-06-11 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, processes for producing the same and utilization thereof
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
SK20052000A3 (sk) * 1998-06-30 2002-08-06 Pfizer Products Inc. Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
PL357109A1 (en) 1999-12-28 2004-07-12 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
KR100464261B1 (ko) * 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3711335A1 (de) * 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4007869A1 (de) * 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
EP0529858A1 (de) 1993-03-03
AU2090892A (en) 1993-02-25
HUT63154A (en) 1993-07-28
CN1069730A (zh) 1993-03-10
NO923253D0 (no) 1992-08-19
AU646966B2 (en) 1994-03-10
US5294713A (en) 1994-03-15
FI923775A (fi) 1993-02-24
CN1078968A (zh) 1993-12-01
DE69222719T2 (de) 1998-03-19
EP0529858B1 (de) 1997-10-15
KR930004287A (ko) 1993-03-22
NO923253L (no) 1993-02-24
HU211141A9 (en) 1995-10-30
CA2076619A1 (en) 1993-02-24
DE69222719D1 (de) 1997-11-20
FI923775A0 (fi) 1992-08-21

Similar Documents

Publication Publication Date Title
DE69222719D1 (de) 2-Piperazinonverbindungen, deren Herstellung und Verwendung
FI96947C (fi) Menetelmä terapeuttisesti aktiivisten N1-(1,2-cis-2-halogeenisyklopropyyli)substituoitujen pyridonikarboksyylihappojohdannaisten valmistamiseksi
ATE71080T1 (de) Bicyclische naphthalinderivate, verfahren zu deren herstellung und ihre verwendung in menschlicher und veterinaerer medizin und kosmetik.
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
ES2096933T3 (es) Compuesto capaz de permanecer en la region intracerebral y utilizacion del mismo.
JPS57145850A (en) Novel carboxylic acid amide and medicine
HU9303009D0 (en) New 2-saccharinyl-methyl-aryl-carboxylat derivatives and pharmaceutical preparations containing said compounds
ATE204880T1 (de) N-acyldipeptide, und pharmazeutische präparate davon
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
DE69120221D1 (de) Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
DE3887611T2 (de) Butensäure-Amide, deren Salze, diese enthaltende pharmazeutische Zusammensetzungen und Verfahren zu deren Herstellung.
PL304334A1 (en) Pharmaceutical composition of gastric protective action, including antiulceric one and method of treating diseases of gastrointestinal tract

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties